Skip to main content
Equibles
ZLAB $24.32 -0.04%
ZLAB logo
ZLAB · Zai Lab Ltd
Track ZLAB — free

Use ZLAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZLAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.32 -0.01 (-0.04%)
Rebalance outlook locked
Customer concentration — top customer 18% of receivables

One customer — 18% of receivables (As of June 30, 2026)

“As of June 30, 2026, our largest customer accounted for approximately 18% of our total accounts receivable collectively.”
View the 10-Q filed Aug 6, 2026
Market Cap
$2.88B
Shares
112.27M
Volume · Oct 2 951.85K Avg daily vol (3M) 947.97K
All webcasts

Earnings call · FY2025 Q3

Zai Lab Ltd (ZLAB) Q3 2025 Earnings Call

Concluded Nov 6, 2025
Nov 6, 2025 0 turns
Period
FY2025 Q3
Runtime
—
Sources
2 artifacts
8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

ZL1503 immunology / atopic dermatitis 16 Pivotal/registrational milestones and BLA submission 10 Regional immunology and partner updates (VivGuard, Vertex) 8 Regional commercial performance and policy support 7 AI and R&D engine productivity 6 Broader pipeline expansion and other oncology assets 6

Management tone

Confident

Net tone +62 · low hedging

Grounding quotes
  • “Responses of this magnitude inside the brain in one of the most treatment-resistant tumor types in oncology are meaningful signals of differentiation.”
  • “Our pipeline is expanding. Our global assets are generating meaningful data, and our lead asset is in global pivotal stage.”
  • “A Registrational Phase III DELEBATE study is enrolling well and is on track to complete enrollment in the first half of 2027, positioning us for an interim analysis and potential accelerated approval submission next year.”
  • “Given our first and best-in-class portfolio, we are confident in Xi's future, which will be defined by our growing global and regional pipeline of differentiated assets.”

Forward guidance

1 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue $116.09M +13.5% YoY
Diluted EPS -$0.03
Net income -$35.96M

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 6, 2025 10-Q report Filed Nov 6, 2025

Forward guidance

From the 8-K filed Nov 6, 2025.

Metric Guided Actual
Total revenue Initiated
full year 2025
 at least $460M $460.16M within

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Zejula$42.43M -12% YoY
Vyvgart Vyvgart Hytrulo$27.73M +1.7% YoY
Nuzyra$15.43M +54.3% YoY
Optune$12.66M +64.1% YoY
Qinlock$8.90M +3% YoY
XACDURO$6.45M
AUGTYRO$1.68M
Product And Service Other$92,000
Full-screen source Call document

ZLAB transcript alerts

Zai Lab Ltd

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →